ResMed Management

Management criteria checks 4/4

ResMed's CEO is Mick Farrell, appointed in Mar 2013, has a tenure of 11.67 years. total yearly compensation is $14.12M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth $109.43M. The average tenure of the management team and the board of directors is 2.8 years and 7 years respectively.

Key information

Mick Farrell

Chief executive officer

US$14.1m

Total compensation

CEO salary percentage8.3%
CEO tenure11.7yrs
CEO ownership0.3%
Management average tenure2.8yrs
Board average tenure7yrs

Recent management updates

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

Nov 13
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

Recent updates

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

Nov 13
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Nov 01
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Oct 20
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Oct 08
ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Why ResMed's Rally Is Just Getting Started

Sep 18

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

Sep 13
ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Aug 05
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Jul 29
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

Jul 15
Returns On Capital Are A Standout For ResMed (NYSE:RMD)

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

Jul 03

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10
Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06
Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01
Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07
ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30
ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02
A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

CEO Compensation Analysis

How has Mick Farrell's remuneration changed compared to ResMed's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$1b

Jun 30 2024US$14mUS$1m

US$1b

Mar 31 2024n/an/a

US$958m

Dec 31 2023n/an/a

US$890m

Sep 30 2023n/an/a

US$907m

Jun 30 2023US$14mUS$1m

US$898m

Mar 31 2023n/an/a

US$863m

Dec 31 2022n/an/a

US$809m

Sep 30 2022n/an/a

US$786m

Jun 30 2022US$12mUS$1m

US$779m

Mar 31 2022n/an/a

US$779m

Dec 31 2021n/an/a

US$522m

Sep 30 2021n/an/a

US$500m

Jun 30 2021US$10mUS$1m

US$475m

Mar 31 2021n/an/a

US$457m

Dec 31 2020n/an/a

US$699m

Sep 30 2020n/an/a

US$680m

Jun 30 2020US$10mUS$1m

US$622m

Mar 31 2020n/an/a

US$513m

Dec 31 2019n/an/a

US$455m

Sep 30 2019n/an/a

US$419m

Jun 30 2019US$10mUS$967k

US$405m

Mar 31 2019n/an/a

US$446m

Dec 31 2018n/an/a

US$450m

Sep 30 2018n/an/a

US$335m

Jun 30 2018US$9mUS$934k

US$316m

Compensation vs Market: Mick's total compensation ($USD14.12M) is about average for companies of similar size in the US market ($USD12.74M).

Compensation vs Earnings: Mick's compensation has been consistent with company performance over the past year.


CEO

Mick Farrell (52 yo)

11.7yrs

Tenure

US$14,120,829

Compensation

Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Farrell
CEO & Chairman11.7yrsUS$14.12m0.31%
$ 109.4m
Peter Farrell
Founderno dataUS$719.69k0.056%
$ 19.7m
Brett Sandercock
Chief Financial Officer18.8yrsUS$3.23m0.065%
$ 22.6m
Michael Rider
Chief Legal Officer & Secretary1.3yrsUS$2.15m0.0064%
$ 2.2m
Justin Leong
Chief Product Officer8.5yrsUS$3.60m0.013%
$ 4.5m
Kaushik Ghoshal
Chief Commercial Officer - SaaS2.8yrsUS$3.53m0.013%
$ 4.6m
Alastair Robertson
Chief Information Officerless than a yearno datano data
Amy Wakeham
Chief Investor Relations Officer1.6yrsno datano data
Jim Ellis
Chief Compliance Officer6.8yrsno datano data
Yvonne-Katrin Pucknat
Chief Marketing Officerless than a yearno datano data
Vered Keisar
Chief People Officer3.7yrsno datano data
Robert Douglas
Special Advisorless than a yearUS$6.67m0%
$ 0

2.8yrs

Average Tenure

57yo

Average Age

Experienced Management: RMD's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Farrell
CEO & Chairman11.7yrsUS$14.12m0.31%
$ 109.4m
Peter Farrell
Founder35.4yrsUS$719.69k0.056%
$ 19.7m
Richard Sulpizio
Independent Director19.3yrsUS$348.72k0.010%
$ 3.6m
Ronald Taylor
Lead Independent Director19.8yrsUS$381.22k0.014%
$ 5.0m
Jan De Witte
Independent Non-Executive Director5.5yrsUS$329.97k0.0046%
$ 1.6m
Harjit Gill
Independent Director6yrsUS$329.97k0.0060%
$ 2.1m
Carol Burt
Independent Director11yrsUS$369.97k0.010%
$ 3.5m
Karen Drexler
Independent Director7yrsUS$334.97k0.0052%
$ 1.8m
Christopher DelOrefice
Independent Directorless than a yearno datano data
Desney Tan
Independent Director3yrsUS$329.97k0.0014%
$ 496.2k
John Hernandez
Independent Director3yrsUS$329.97k0.0014%
$ 496.2k

7.0yrs

Average Tenure

60yo

Average Age

Experienced Board: RMD's board of directors are considered experienced (7 years average tenure).